We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
-1.68%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$120M
AUM Growth
+$37.7M
Cap. Flow
+$41.9M
Cap. Flow %
34.93%
Top 10 Hldgs %
71.57%
Holding
35
New
11
Increased
11
Reduced
1
Closed
12

Top Buys

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$12.6M
2
ASND icon
Ascendis Pharma A/S
ASND
+$7.21M
3
PCRX icon
Pacira BioSciences
PCRX
+$6.33M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$5.61M
5
CHRS icon
Coherus Oncology
CHRS
+$5.49M

Top Sells

Rank Stock Value
1
HRTX icon
Heron Therapeutics
HRTX
+$9.5M
2
BHC icon
Bausch Health
BHC
+$5.08M
3
STML
Stemline Therapeutics, Inc.
STML
+$4.18M
4
NVS icon
Novartis
NVS
+$3.83M
5
CBAY
Cymabay Therapeutics
CBAY
+$2.79M

Sector Composition

Rank Sector Weight
1 Healthcare 92.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ICPT
1
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$12.1M 10.1%
152,441
+140,489
+1,175% +$12.6M
INSM icon
2
Insmed
INSM
$23.5B
$12.1M 10.04%
470,741
+186,478
+66% +$5.19M
BOLD
3
DELISTED
Audentes Therapeutics, Inc
BOLD
$11.1M 9.27%
294,013
+43,393
+17% +$1.67M
NBIX icon
4
Neurocrine Biosciences
NBIX
$17.2B
$7.8M 6.5%
92,380
+68,340
+284% +$5.61M
SRPT icon
5
Sarepta Therapeutics
SRPT
$1.82B
$7.65M 6.37%
50,317
+29,047
+137% +$3.53M
GBT
6
DELISTED
Global Blood Therapeutics, Inc.
GBT
$7.49M 6.23%
142,305
+55,206
+63% +$3.17M
IMMU
7
DELISTED
Immunomedics Inc
IMMU
$7.27M 6.06%
524,140
+189,416
+57% +$2.85M
CHRS icon
8
Coherus Oncology
CHRS
$216M
$6.99M 5.82%
+316,316
New +$5.49M
ASND icon
9
Ascendis Pharma A/S
ASND
$17.1B
$6.94M 5.78%
+60,266
New +$7.21M
PCRX icon
10
Pacira BioSciences
PCRX
$1.01B
$6.48M 5.4%
+149,086
New +$6.33M
URGN icon
11
UroGen Pharma
URGN
$1.96B
$6.36M 5.29%
176,866
+44,277
+33% +$1.63M
QURE icon
12
uniQure
QURE
$2.77B
$4.68M 3.9%
59,883
+21,083
+54% +$1.34M
AMRN
13
Amarin Corp
AMRN
$292M
$4.46M 3.72%
11,515
+4,080
+55% +$1.49M
ABBV icon
14
AbbVie
ABBV
$450B
$3.83M 3.19%
+52,681
New +$4.14M
BHVN
15
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$3.77M 3.14%
+86,165
New +$4.86M
VTRS icon
16
Viatris
VTRS
$20.1B
$1.95M 1.63%
+102,560
New +$2.27M
ITCI
17
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$1.86M 1.55%
+143,665
New +$1.84M
REGN icon
18
Regeneron Pharmaceuticals
REGN
$70.9B
$1.77M 1.48%
+5,668
New +$1.89M
MDGL icon
19
Madrigal Pharmaceuticals
MDGL
$12.8B
$1.62M 1.35%
15,423
+11,971
+347% +$1.28M
DERM
20
DELISTED
Dermira, Inc.
DERM
$1.32M 1.1%
+138,102
New +$1.49M
GILD icon
21
Gilead Sciences
GILD
$167B
$1.26M 1.05%
+18,697
New +$1.23M
ANAB icon
22
AnaptysBio
ANAB
$1.72B
$679K 0.57%
+12,026
New +$866K
AGN
23
DELISTED
Allergan plc
AGN
$560K 0.47%
3,347
-10,353
-76% -$1.43M
BHC icon
24
Bausch Health
BHC
$1.8B
– –
-205,660
Closed -$5.08M
BMRN icon
25
BioMarin Pharmaceuticals
BMRN
$11.5B
– –
-8,250
Closed -$733K
1
2

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q2 2019 Portfolio in Review

As of Q2 2019, Nexthera Capital held 35 positions worth $120M, up 46% from $82.4M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Nexthera Capital deployed $41.9M of net new capital in Q2 2019, opening 11 new positions and adding to 11 existing holdings. Its largest new stake was Ascendis Pharma A/S: 60,266 shares worth $6.94M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier.

On the sell side, the largest reduction was Allergan plc, an estimated $1.43M trimmed.

  • Nexthera Capital's largest Q2 2019 buy was Ascendis Pharma A/S: 60,266 shares worth $6.94M.
  • Nexthera Capital added most to Intercept Pharmaceuticals, Inc. in Q2 2019, an estimated $12.6M increase.
  • Nexthera Capital's biggest Q2 2019 reduction was Allergan plc, cutting an estimated $1.43M.
  • Nexthera Capital fully exited Heron Therapeutics in Q2 2019, selling an estimated $9.5M.
  • Nexthera Capital's ten largest holdings make up 72% of its $120M portfolio in Q2 2019.
  • Nexthera Capital opened 11 new positions and closed 12 in Q2 2019.
  • Nexthera Capital's portfolio value rose 46% quarter-over-quarter to $120M.

Based on Nexthera Capital's 13F filing for Q2 2019, filed 14 Aug 2019.